Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biocodex Introduces Precision Probiotic Fullify to Support Appetite Management - Nutraceuticals World

What are you searching for?

Sign in
Products & Ingredients

Biocodex Introduces Precision Probiotic Fullify to Support Appetite Management

Developed in France and now available in the U.S., Fullify contains Hafnia alvei HA4597, a clinically studied probiotic strain that supports the body’s natural fullness signals.

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Photo courtesy of Biocodex

Biocodex, the company behind Florastor, has introduced Fullify, a probiotic developed to support appetite management and weight loss by working with the body’s natural gut-brain signaling.

Developed in France and now available in the U.S., Fullify contains Hafnia alvei HA4597, a clinically studied probiotic strain that supports the body’s natural fullness signals, the company said.

By working through the gut-brain pathway, Fullify reportedly stimulates production of ClpB, a protein that then stimulates production of GLP-1 and PYY hormones, leading to satiety, less hunger, and fewer cravings.

“For decades, weight management has been treated as a discipline problem when in reality, it’s deeply biological,” said Bindu Shah, chief marketing officer at Biocodex. “Fullify is the result of more than 10 years of research into the gut-brain pathway, translating real science into a completely new approach. This innovation isn’t about suppressing appetite or relying on stimulants; it’s about working with the body’s natural signaling to support more realistic and attainable outcomes. Bringing this level of science to a consumer product is incredibly meaningful to us, and it reflects a new direction for the category.”

Fullify was developed through more than 10 years of research, including two preclinical studies and a placebo-controlled human clinical trial. In a 12-week clinical study of more than 300 overweight adults following a calorie-restricted diet, participants taking Hafnia alvei HA4597 demonstrated significantly better outcomes than those following diet alone. Individuals in the Fullify group were 50% more likely to lose more than 4% of their body weight compared with those in the placebo group.

An additional survey-based study was conducted with consumers, which revealed meaningful changes beyond weight loss. Users in this study reported improved eating behaviors, increased feelings of fullness after meals, and reduced cravings compared with baseline.

Made exclusively in France and used in Europe since 2023, Fullify should be taken twice daily with meals.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics